Gurgaon-based Ranbaxy Laboratories has reportedly pulled off fresh stock of Isotretinoin 20 mg capsules from the UK market following an order from the European Commission. Isotretinoin is used for treating severe skin conditions. According to a statement issued on the official website of the UK Medicines and Healthcare Products Regulatory Agency’s (MHRA), the company’s UK arm, Ranbaxy (UK) Ltd is recalling all unexpired stock of this product following a decision made by the European Commission that the marketing authorization should be suspended as a temporary measure, citing a possible issue with bioequivalence as the reason.
Must Read
Latest News
India leads in GenAI adoption, investment trends likely to rise in coming years: Report
The study also predicted promising investment trends shortly, with about 94% of respondents anticipating increased investments and budget allocations...